GlassScriptPhysician profile
David Bradley Amos
NPI 1689650749
$25,064.84
in general payments reported to CMS, 2019-2025
37 companies · $3,441 in 2025
The $3,441 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,546 · 2020: $4,049 · 2021: $3,502 · 2022: $3,214 · 2023: $3,736 · 2024: $3,577 · 2025: $3,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,687.89 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,005.24 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Galderma Laboratories, L.P. | $2,652.78 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Janssen Biotech, INC. | $2,304.33 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,596.58 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,334.25 | 2019-2025 | Dupixent, Libtayo |
| Epi Health, LLC | $1,130.73 | 2020-2022 | |
| Amgen INC. | $1,011.22 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $1,007.06 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $992.21 | 2019-2025 | |
| Incyte Corporation | $950.60 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $943.09 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $894.88 | 2019-2025 | Ilumya, Blu-U, Winlevi |
| Leo Pharma INC. | $747.24 | 2019-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $681.12 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $662.10 | 2021-2025 | Bimzelx, Cimzia |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Amos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.